Ranbaxy Laboratories, Inc.

Sun Pharmaceutical Industries Limited

Chandra Has Khanduri

Mukesh Kumar Madhra

Ramkinkar Santra

Pankaj Kumar Singh

Mohammed Salman Hashmi

Bala Krishna Reddy Bhogala

Yatendra Kumar

Ram Chander Aryan

Mukesh Kumar Sharma

Purna Chandra Ray

Jayachandra Suresh Babu

Parendn Dhirajlal Rathod

Yoginder Pal Sachdeva

Satish Kumar Aryan

Parendu Dhirajlal Rathod

The present invention relates to crystalline forms of ibrutinib, designated as Form S1, Form S2, Form S3, Form S4, and an amorphous form, designated as Form A1, and processes for their preparation, pharmaceutical compositions comprising these forms, and their use for the treatment of Bruton's tyrosine kinase (BTK) mediated diseases.

Crystalline forms of ibrutinib

The present invention relates to processes for the preparation of an ertugliflozin-L-pyroglutamic acid (1:1) and co-crystal ertugliflozin-L-proline (1:1) co-crystal. The present invention further relates to an ertugliflozin-L-proline (1:2) co-crystal, processes for its preparation, and its use for the treatment of type 2 diabetes mellitus.

Ertugliflozin co-crystals and process for their preparation

The present invention provides compounds of Formula III and Formula VI, and processes for their preparation. The present invention further provides use of the compounds of Formula III and Formula VI for the preparation of tofacitinib or isomers or a mixture of isomers or salts thereof. 

Process for the preparation of tofacitinib and intermediates thereof

The present invention provides a novel process for the preparation of pure valganciclovir hydrochloride.

Process for the preparation of valganciclovir hydrochloride

The present invention is concerned with novel compounds and their use for the preparation of lacosamide. The present invention also contemplates processes for the preparation of lacosamide employing the novel compound of general Formula II, Formula IIa or Formula IIb as intermediate. Wherein

Intermediate compounds and their use in preparation of lacosamide

The present invention provides a process for the preparation of clopidogrel and its pharmaceutically acceptable salts thereof comprises the resolving racemic methyl alpha-5-(4,5,6,7-tetrahydro[3,2-c]thienopyridyl)(2-chlorophenyl)-acetate by the salt formation of methyl alpha-5-(4,5,6,7-tetrahydro[3,2-c]thienopyridyl)(2-chlorophenyl)-acetate with excess levorotatory camphor-10-sulfonic acid to get a maximum yield of camphor sulphonate salt of methyl S-(+)-alpha-5-(4,5,6,7-tetrahydro[3,2-c]thienopyridyl) (2-chlorophenyl)-acetate and transforming the camphor sulphonate salt to clopidogrel or its pharmaceutically acceptable salts thereof.

Process for the preparation of clopidogrel and its pharmaceutically acceptable salts

The present invention relates to an industrial useful process for the synthesis of antiviral compound, ganciclovir which comprises dissolving a mixture containing N-7 and N-9 isomers of structural formulae, II and III, respectively:in a solvent or a mixture of solvents; separating the N-7 and N-9 isomers; and hydrolizing the N-9 isomer to obtain ganciclovir.

Growing community of inventors

Gurgaon, India

Chandra Has Khanduri